Osso VR, which uses VR simulations to train surgeons, raises a $66M Series C led by Oak HC/FT, bringing its total funding to about $109M
Sarah Pringle / Axios :
Context & Ripple Effects
Osso VR's Series C is the third step of a fast-stacked ladder: a $14M Series A built on Oculus Quest headsets in 2020, a $27M round led by GSR Ventures in mid-2021, and now $66M from healthcare specialist Oak HC/FT that lifts total funding to roughly $109M. The round size more than doubling between rounds signals investors see surgical simulation moving from pilot deployments toward standard training infrastructure.
The raise lands in a category where capital is arriving on multiple fronts at once: FundamentalVR closed a $20M round months later for its cross-platform medical simulation tool, while AppliedVR and Oxford VR have been raising for VR-based therapeutics rather than training — together marking medical VR as a funded vertical on both the clinician-education and patient-treatment sides.
First-order effects
- Oak HC/FT's healthcare-focused check gives Osso VR roughly $109M of total runway to scale its surgeon-training simulations beyond early hospital and medical-device customers, with the lead investor's health portfolio likely opening doors to provider systems.
Second-order effects
- FundamentalVR's own $20M raise confirms rivals are being capitalized in parallel, pushing competition toward platform breadth — cross-platform support versus headset-specific content — rather than proving the category works.
- Medical-device makers, whose products surgeons must learn to use, become the natural distribution channel: whoever owns the simulation layer gains leverage over how new devices get adopted in operating rooms.
Third-order effects
- If funding cadence holds, surgical training splits into a software-defined segment where VR simulation is the default first pass before cadaver labs and supervised cases — shifting spending from physical training facilities to content platforms.
- The parallel funding of training tools like Osso VR and therapeutics players like AppliedVR points toward regulators and payers eventually treating validated VR software as reimbursable clinical infrastructure, not experimental equipment.
The trend: Medical VR is consolidating into a funded vertical with two tracks — clinician training and patient therapeutics — where specialized healthcare investors are picking category leaders before revenue scales.